| 摘要 |
<p>The invention relates to the ophthalmologic applications of a formulation of a Rofecoxib suspension (specific inhibitor of cyclooxygenase isoform 2 (COX-2)) which is used for the following: treatment of cystoid macular oedema in the retina (phakic and pseudophakic); prevention of transoperative miosis; definitive or adjuvant treatment of the following conditions, which are accompanied by intraocular inflammation: anterior uveitis, iritis, cyclitis, iridocyclitis, trabeculitis, intermediate uveitis, posterior uveitis (choroiditis, retinitis, chorioretinitis, retinochoroiditis), optic neuritis; definitive or adjuvant treatment of all known variants of glaucoma, both open angle and closed angle, primary and secondary; definitive or adjuvant treatment of allergic conjunctival disease, including stable allergic conjunctivitis, vernal conjunctivitis, atopic blepharoconjunctivitis, giant papillary conjunctivitis and contact conjunctivitis; treatment of chronic and acute non-specific, non-infectious conjunctiva, and symptomatic management of infectious viral, bacterial and mycotic conjunctiva using both protozoa and helminths; definitive or adjuvant treatment of external inflammatory diseases, including keratitis, scleritis (necrotising and non-necrotizing, anterior and/or posterior), episcleritis (nodular and diffuse), and symptomatic management of pingueculitis and pterygium; and post-operative treatment following any surgical procedure involving the eyeball and/or its appendages.</p> |
